Enlivex Therapeutics Ltd
1BT
Company Profile
Business description
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
Contact
14 Einstein Street
Ness Ziona7403618
ISRT: +972 26208072
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
36
Stocks News & Analysis
stocks
Chart of the Week: We see opportunity in Mineral Resources despite debt concerns
Shares trade at a discount despite attractive longer-term outlook.
stocks
The ultimate investing hack: dividend growth stocks
Finding companies built for lasting dividend growth.
stocks
Is the data centre party over for Goodman?
Global spending spree on data centres could mean a declining return on invested capital.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,887.50 | 29.00 | -0.33% |
| CAC 40 | 8,087.42 | 12.81 | 0.16% |
| DAX 40 | 23,693.71 | 17.15 | -0.07% |
| Dow JONES (US) | 47,882.90 | 408.44 | 0.86% |
| FTSE 100 | 9,692.07 | 9.73 | -0.10% |
| HKSE | 25,760.73 | 334.32 | -1.28% |
| NASDAQ | 23,454.09 | 40.42 | 0.17% |
| Nikkei 225 | 50,223.34 | 358.66 | 0.72% |
| NZX 50 Index | 13,485.86 | 96.68 | -0.71% |
| S&P 500 | 6,849.72 | 20.35 | 0.30% |
| S&P/ASX 200 | 8,591.40 | 27.40 | -0.32% |
| SSE Composite Index | 3,878.00 | 19.71 | -0.51% |